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ABSTRACT: Pseudomonas aeruginosa is a Gram-negative bacterium causing skin and soft tissue infections, 
complicated urinary tract infections, blood infections, and nosocomial (hospital-acquired) infections. One of 
the most often used antiseptics in the skin and soft tissue infections is octenidine dihydrochloride. The aim of 
this study was an evaluation of octenidine activity against strains of P. aeruginosa. Additionally, were 
compared two staining methods (TTC and MTT) for confirmation of bacterial growth. The study involved 
eight strains of P. aeruginosa. In order to determine the minimum inhibitory concentration (MIC) of 
octenidine, the microdilution method was used. For bacterial growth detection was used staining method with 
2,3,5-triphenyl-tetrazolium chloride (TTC) and with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT). In the study has been demonstrated the excellent activity of octenidine against all 
strains of Pseudomonas aeruginosa. For all tested strains, MICs of octenidine were 0.00039% or 0.00078%, 
what is equivalent to 3.9 µg/ml and 7.8 µg/ml, respectively. In the study, test with MTT for three strains was 
more sensitive than a test with TTC. Concluding, octenidine is an antiseptic with high efficacy against 
Pseudomonas aeruginosa strains. Simultaneously, it was stated that a test with MTT is more sensitive than 
study with TTC.  
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1. INTRODUCTION 
 Pseudomonas aeruginosa is a ubiquitous Gram-negative rod bacterium belonging to the family 
Pseudomonadaceae [1]. P. aeruginosa is oxidase-positive, non-fermenting lactose, with low nutritional 
requirements. It shows the ability to survive in different conditions, including a nutrient-poor environment 
(distilled water) and in a wide temperature range (from 4 to 44 °C). This pathogen produces a phenazine blue 
dye called pyocyanin [2]. P. aeruginosa has many virulence factors, including bacterial cell-associated 
lipopolysaccharides (LPS), fimbriae, flagellae, mucus, lectins, exotoxin A, exoenzymes, alkaline protease, 
type IV protease, type A and B elastase, neuraminidase, hemolytic and non-hemolytic phospholipase, and 
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pyocyanin [3]. P. aeruginosa is an opportunistic pathogen and has recently been classified as an ESKAPE 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species) pathogen. This group contains highly resistant bacteria 
causing nosocomial (hospital-acquired) infections [4]. The intrinsic resistance of P. aeruginosa to antibiotics 
is conditioned by three mechanisms: 
1. active removal of the antibiotic from the cell (efflux system),  
2. reduced permeability of the outer membrane, 
3. enzymatic inactivation of the antibiotic [5].  
 All P. aeruginosa strains are naturally resistant to penicillin G, aminopenicillin, cephalosporins of the 
first and second generation, macrolides, tetracyclines, chloramphenicol, quinolones, sulfonamides, and 
trimethoprim [6, 7]. P. aeruginosa is highly associated with nosocomial infections and ventilator-associated 
pneumonia [8]. This bacterium also causes skin and soft tissue infections, complicated urinary tract infections, 
and blood infections [9]. European Centre for Disease Prevention and Control presented that in 2016 in 
Europe, 33.9% of P. aeruginosa strains were resistant to at least one of the antimicrobial groups under 
surveillance (piperacillin ± tazobactam, fluoroquinolones, ceftazidime, aminoglycosides, and carbapenems) 
[10]. In these studies, in Latvia, Poland, Slovakia, Hungary, Croatia, Serbia, Bulgaria and Greece, 25-50% of 
P. aeruginosa isolates were resistant to carbapenems, while in Romania more than 50% of the strains. 
Combined resistance to three or more antimicrobials was in 25-50% of the strains isolated in Slovakia, 
Romania, Croatia, Bulgaria, and Greece. The World Health Organization (WHO) has recently listed 
carbapenem-resistant P. aeruginosa as one of three bacterial species in which there is a critical need for the 
development of new antibiotics to treat infections [11].  
 Octenidine dihydrochloride (OCT; 1,1'-(1,10-Decanediyl)bis(N-octyl-4(1H)-pyridinimine) 
dihydrochloride) is a bispyridine compound with 2 cationic active centers. This substance has a molecular 
formula C36H64Cl2N4 and molecular weight 623.826 g/mol [12]. Chemical structure of octenidine is presented 
in Figure 1. OCT contains antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi, 
and several viruses [13, 14]. OCT has good activity against bacteria Staphylococcus epidermidis, 
Staphylococcus aureus, Enterococcus faecalis, Klebsiella pneumoniae, Serratia marcescens, Pseudomonas 
aeruginosa, and the fungus Candida albicans [13-19]. It acts bactericidal/fungicidal by interfering with cell 
walls and membranes [20]. OCT is relatively non-cytotoxic [14], and does not affect the human epithelium 
and the healing process [21].   
 
 
 
   Figure 1. Chemical structure (left 2D and right 3D) of octenidine dihydrochloride. 
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 The aim of this study was an evaluation of octenidine activity against strains of Pseudomonas 
aeruginosa. Additionally, were compared two staining methods (TTC and MTT) for bacterial growth 
detection. 
2. MATERIALS AND METHODS 
 The study involved eight strains of Pseudomonas aeruginosa. Six isolates were from wounds as part of 
the service activity of the Department of Medical Microbiology, Poznań University of Medical Sciences. Two 
were reference strains: P. aeruginosa ATCC 27853 (Boston 41501) and ATCC BAA-47 (4901; PAO1). 
Bacteria were grown on cetrimide agar (Oxoid) for 18-24 h at 37°C. 
 In order to determine the minimum inhibitory concentration (MIC) of octenidine, the microdilution 
method was used on polystyrene 96-well plates (Nunc). The octenidine dihydrochloride (Octenisept, Schülke) 
was appropriately diluted on the plates to obtain concentrations ranging from 0.000195 to 0.1%. A suspension 
with a density of 1 × 108 cells/ml (0.5 McF) was prepared for each strain. The suspension was diluted 10-fold 
with TSB to obtain a bacterial suspension with a density of 1 × 107 cells/ml. 10 μl of bacterial suspension was 
transferred to appropriate wells (2-12) of the plate. Well no. 1 was the negative control, filled with 100 μl of 
Mueller Hinton broth (MHB). Well no. 2 was also the negative control but filled with 10 μl of bacterial 
suspension and 100 μl of disinfectant agent Aerodesin 2000 (Lysoform), containing propan-1-ol 32.5 g, 
ethanol 18 g, and glutaraldehyde 0.1 g. A plate with appropriate suspensions of bacterial cells was incubated 
for 24 hours at 37°C. Two rows of wells were prepared for each strain. 2,3,5-triphenyl-tetrazolium chloride 
(20 μl, 1% TTC, Sigma-Aldrich) was added to the wells of the first row. After 24 h of culture, the optical 
density at the wavelength λ = 495 nm was measured. In the presence of live, metabolically active 
microorganisms, colorless TTC is reduced to red formazan. To the wells of the second row, after 24 h culture, 
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (25 μl, 3% MTT, Sigma-Aldrich) was 
added and incubated 2 hours at 37°C. Then, the optical density at the wavelength λ = 554 nm was measured. 
This assay is based on the reduction of yellow tetrazolium salt (MTT) to a soluble purple/blue formazan 
product [21]. MIC is the lowest concentration of an antimicrobial agent in which no growth of a 
microorganism is observed [22]. The MIC was the concentration of the octenidine in the first well, in which 
after incubation, the color did not change. Each measurement was carried out in triplicate. 
3. RESULTS 
 In the present study has been demonstrated the excellent activity of octenidine against all strains of 
Pseudomonas aeruginosa. For all tested strains, MICs of octenidine were 0.00039% or 0.00078%, what is 
equivalent to 3.9 µg/ml and 7.8 µg/ml, respectively. Simultaneously, it was stated the difference between 
studies with MTT and TTC. Test with MTT for three strains (2, 4, and 41501) was more sensitive than study 
with TTC (Figure 2).  
4. DISCUSSION 
 Octenidine is an antiseptic used clinically in concentrations 0.05% (500 µg/ml) or 0.1% (1000 µg/ml). 
In this work is presented that bactericidal level of OCT against Pseudomonas aeruginosa is ranging from 
0.00039% (3.9 µg/ml) to 0.00078% (7.8 µg/ml). Bartoszewicz et al. obtained for P. aeruginosa MICs of OCT 
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between 3.91 and 125 µg/ml, and MIC90 was 62.5 µg/ml [16]. Koburger et al. demonstrated for octenidine 
MIC24 = 2 and MIC48 = 8 µg/ml against P. aeruginosa. MICs of OCT against other bacteria are following, e.g. 
for Staphylococcus aureus 0.24-7.81 µg/ml, S. epidermidis 125 µg/ml, Enterococcus faecalis 4 µg/ml, 
Esherichia coli 2 µg/ml, Streptococcus mutans 120 µg/ml and Lactobacilli 15-30 µg/ml [16, 24, 25]. 
 
 
Figure 2. Study of bactericidal activity of octenidine (OCT) against eight strains of Pseudomonas aeruginosa. Obtained 
MICs are 0.00039 and 0.00078% of octenidine. 
 
 Differences between MIC levels depend, among others on whether the bacteria were tested in 
planktonic or biofilm form, which is less sensitive to antiseptics. Shepherd et al. presented the possibility of 
increased tolerance to OCT of P. aeruginosa [26]. Authors in seven strains of P. aeruginosa showed the initial 
MICs 4-8 µg/ml. After 12 days of adaptation study, MICs were 32-128 µg/ml. Unfortunately, the highest used 
OCT concentration (64 µg/ml = 0.0064%) was about 10-fold lower than the clinical doses. Moreover, at OCT 
level 32 µg/ml one strain did not grow, and a concentration of 64 µg/ml caused no growth in up to 3 (43%) 
strains [26]. The phenomenon of adaptation in such low concentrations does not seem to have any significant 
clinical significance. It can be stated that preparations of OCT in clinical doses remained fully effective 
against bacteria, especially P. aeruginosa. It is also extremely important that no resistance to OCT has been 
found so far. Such resistance has been demonstrated, among others for chlorhexidine [27-29].   
 Concluding, octenidine is an antiseptic with high efficacy against Pseudomonas aeruginosa strains. 
Simultaneously, it was stated that a test with MTT is more sensitive than study with TTC.  
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